Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Eligible age
18+ yrs
Accepts
All genders
Locations
27 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
Sponsor: Merck Sharp & Dohme LLC
You may qualify if…
- ✓ Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
- ✓ Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
- ✓ Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
- ✓ Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
- ✓ Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
- ✓ Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM)
- ✓ Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
- ✓ Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
You may not qualify if…
- ✕ Has a gastrointestinal disorder that might affect absorption
- ✕ Has a history of pituitary dysfunction
- ✕ Has poorly controlled diabetes mellitus
- ✕ Has clinically significant abnormal serum potassium or sodium level
- ✕ Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
- ✕ Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization
- ✕ Has a history of clinically significant ventricular arrhythmias
- ✕ Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization
Where it's recruiting
Orange · Palo Alto · Riverside
Aurora · Highlands Ranch · Lakewood · Lone Tree
New Haven
Fort Myers · Miami
Chicago
Iowa City
Lexington
New Orleans
Baltimore
Detroit
Marshall · Minneapolis · Saint Louis Park
Hattiesburg
Source: ClinicalTrials.gov · NCT06136624 · last updated 2026-11-13